Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in NETs

Peter M. Anderson • 25 May 2021
ASCO 2021
Gastrointestinal Cancer Neuroendocrine Tumor ONC201

Peter M. Anderson, MD, PhD , Cleveland Clinic, Cleveland, OH, discusses the findings of a Phase II study of the DRD2 antagonist/CIpP agonist ONC201 in neuroendocrine tumors (NETs). ONC201 was found to be well tolerated in adults with advanced NETs, particularly in paraganglioma patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Peter M. Anderson

1:26
Personalized medicine in NETs
Peter M. Anderson • 25 May 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals